Trials / Completed
CompletedNCT06414798
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
A First-in-Human Single Ascending Dose, Mass Balance, and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug: ABBV-1088 | • Oral Capsule |
| DRUG | Drug: Placebo for ABBV-1088 | • Oral Capsule |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2025-02-08
- Completion
- 2025-02-08
- First posted
- 2024-05-16
- Last updated
- 2025-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06414798. Inclusion in this directory is not an endorsement.